What are the recommended dosing regimens of ergocalciferol (vitamin D₂) for treating vitamin D deficiency in adults, children, pregnant or lactating women, and patients with chronic kidney disease?

Ergocalciferol Dosing for Vitamin D Deficiency

For treating vitamin D deficiency in adults and children with CKD, use ergocalciferol 50,000 IU weekly for severe deficiency (25(OH)D <5 ng/mL), 50,000 IU every other week for mild deficiency (5-15 ng/mL), or 50,000 IU every 4 weeks for insufficiency (16-30 ng/mL), followed by maintenance dosing of 200-1,000 IU daily once 25(OH)D reaches ≥30 ng/mL. 1

General Adult Population (Without CKD)

Prevention Dosing

• Adults under 60 years: 400 IU daily 1
• Adults over 60 years: 800 IU daily 1
• Upper safety limit: 2,000 IU/day for adults (can be achieved with 50,000 IU once monthly) 1

Treatment of Severe Deficiency (25(OH)D ≤5 ng/mL)

• Ergocalciferol 50,000 IU weekly for 12 weeks, then monthly thereafter 1
• This regimen addresses rickets or osteomalacia risk 1

Children and Adolescents

Prevention

• 200 IU daily for children and adolescents (though this DRI value is considered controversial and potentially insufficient) 1
• Upper limit for infants <12 months: 1,000 IU/day 1
• Upper limit for all other ages: 2,000 IU/day 1

Treatment Based on Severity (Children with CKD)

Severe deficiency (25(OH)D <5 ng/mL):

• 8,000 IU daily for 4 weeks OR 50,000 IU weekly for 4 weeks 1
• Then 4,000 IU daily for 2 months OR 50,000 IU twice monthly for 2 months 1

Mild deficiency (25(OH)D 5-15 ng/mL):

• 4,000 IU daily for 12 weeks OR 50,000 IU every other week for 12 weeks 1

Insufficiency (25(OH)D 16-30 ng/mL):

• 2,000 IU daily OR 50,000 IU every 4 weeks 1

Maintenance After Repletion

• 200-1,000 IU daily once 25(OH)D ≥30 ng/mL is achieved 1
• Smaller doses are likely sufficient for children under 1 year 1

Patients with Chronic Kidney Disease

CKD Stages 3-5 (Not on Dialysis)

• Same treatment regimens as above based on deficiency severity 1
• Cholecalciferol (vitamin D3) appears to have higher bioefficacy than ergocalciferol, though long-term comparative trials are lacking 1
• Do NOT use calcitriol or active vitamin D analogs (doxercalciferol, paricalcitol) to treat 25(OH)D deficiency 1

CKD Stage 5D (Dialysis Patients)

• Ergocalciferol 72,000 IU weekly for 12 weeks, then 24,000 IU weekly as maintenance has been shown effective and safe 2
• Alternative: 50,000-100,000 IU weekly is more likely to achieve sufficiency compared to lower doses 3
• High doses up to 10,000 IU daily have been administered for >1 year without toxicity in advanced CKD 1
• Even anephric patients can benefit from ergocalciferol through extrarenal 1α-hydroxylase activity 1

Pregnant and Lactating Women

• No specific ergocalciferol dosing recommendations are provided in the guidelines for pregnancy 4
• Recent evidence suggests empiric vitamin D supplementation during pregnancy may lower risks of preeclampsia, preterm birth, and neonatal mortality 4
• Standard treatment regimens for deficiency should be applied with caution and monitoring

Important Clinical Considerations

Safety Monitoring

• Hypercalcemia is the primary sign of excessive dosing 1
• Avoid 25(OH)D levels >150-200 nmol/L (60-80 ng/mL) to reduce toxicity risk 5
• Avoid mega-doses ≥100,000 IU to minimize toxicity 5
• Monitor calcium and phosphate levels, especially in CKD patients 1

Factors Affecting Response

• Obesity (BMI ≥30 kg/m²) decreases likelihood of achieving sufficiency; higher doses may be needed 3, 6
• Glomerular disease requires higher doses compared to non-glomerular CKD 7
• Nephrotic-range proteinuria increases vitamin D losses, requiring higher supplementation 1
• Dark skin pigmentation and age >60 years reduce endogenous vitamin D synthesis 1

Dosing Preferences

• Daily dosing is preferred over intermittent high doses in adults >50 years when supplementation is indicated 4
• Both daily and weekly regimens achieve similar 25(OH)D concentrations in children with CKD 7
• 50,000-100,000 IU weekly regimens are significantly more effective than <50,000 IU weekly 3

Target Levels

• Goal 25(OH)D concentration: ≥30 ng/mL (≥75 nmol/L) for repletion 1, 5
• Some experts recommend targeting >30 ng/mL for optimal health benefits 5

Common Pitfalls

• Do not confuse nutritional vitamin D (ergocalciferol/cholecalciferol) with active vitamin D analogs (calcitriol, alfacalcidol, doxercalciferol, paricalcitol) - they are NOT interchangeable for treating 25(OH)D deficiency 1
• Routine 25(OH)D screening is not recommended in the general population without risk factors 4
• Available formulations in the US are limited to 400 IU (over-the-counter) and 50,000 IU capsules (prescription) 1